Intracerebroventricular infusion of nerve growth factor in three patients with Alzheimer's disease

被引:339
|
作者
Jönhagen, ME
Nordberg, A
Amberla, K
Bäckman, L
Ebendal, T
Meyerson, B
Olson, L
Seiger, Å
Shigeta, M
Theodorsson, E
Viitanen, M
Winblad, B
Wahlund, LO
机构
[1] Huddinge Univ Hosp, Karolinska Inst, Dept Clin Neurosci & Family Med, Div Geriatr Med, S-14186 Huddinge, Sweden
[2] Uppsala Univ, Biomed Ctr, Dept Dev Neurosci, Uppsala, Sweden
[3] Karolinska Inst, Karolinska Hosp, Dept Clin Neurosci, Neurosurg Sect, S-10401 Stockholm, Sweden
[4] Karolinska Inst, Dept Neurosci, S-10401 Stockholm, Sweden
[5] Linkoping Univ Hosp, Dept Clin Chem, S-58185 Linkoping, Sweden
[6] Jikei Univ, Sch Med, Dept Psychiat, Tokyo, Japan
关键词
nerve growth factor; Alzheimer's disease; cognitive deficits; electroencephalography; positron emission tomography; pain; weight loss; nicotinic receptors;
D O I
10.1159/000017069
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
Nerve growth factor (NGF) is important for the survival and maintenance of central cholinergic neurons, a signalling system impaired in Alzheimer's disease, We have treated 3 patients with Alzheimer's disease with a total of 6.6 mg NGF administered continuously into the lateral cerebral ventricle for 3 months in the first 2 patients and a total of 0.55 mg for 3 shorter periods in the third patient, The patients were extensively evaluated with clinical, neuropsychological, neurophysiological and neuroradiological techniques, Three months after the NGF treatment ended, a significant increase in nicotine binding was found in several brain areas in the first 2 patients and in the hippocampus in the third patient as studied by positron emission tomography. A clear cognitive amelioration could not be demonstrated, although a few neuropsychology tests showed slight improvements, The amount of slow-wave cortical activity as studied by electroencephalography was reduced in the first 2 patients. Two negative side effects occurred with NGF treatment: first, a dull, constant back pain was observed in all 3 patients, which in 1 patient was aggravated by axial loading resulting in sharp, shooting pain of short duration, When stopping the NGF infusion, the pain disappeared within a couple of days, Reducing the dose of NGF lessened the pain. Secondly, a marked weight reduction during the infusion with a clear weight gain after ending the infusion was seen in the first 2 patients. We conclude from this limited trial that, while long-term intracerebroventricular NGF administration may cause certain potentially beneficial effects, the intraventricular route of administration is also associated with negative side effects that appear to outweigh the positive effects of the present protocol, Alternative routes of administration, and/or lower doses of NGF, perhaps combined with low doses of other neurotrophic factors, may shift this balance in favor of positive effects.
引用
收藏
页码:246 / 257
页数:12
相关论文
共 50 条
  • [31] Nerve growth factor gene therapy in Alzheimer disease
    Tuszynski, Mark H.
    [J]. ALZHEIMER DISEASE & ASSOCIATED DISORDERS, 2007, 21 (02): : 179 - 189
  • [32] Role of nerve growth factor on cognitive impairment in patients with Alzheimer's disease carrying apolipoprotein E ε4
    He, Mingyue
    Liu, Zhan
    Lian, Tenghong
    Guo, Peng
    Zhang, Wenjing
    Huang, Yue
    Zhang, Yanan
    Liu, Gaifen
    Zhang, Weijiao
    Li, Jinghui
    Guan, Huiying
    Zhang, Weijia
    Luo, Dongmei
    Qi, Jing
    Yue, Hao
    Wang, Xiaomin
    Zhang, Wei
    [J]. CNS NEUROSCIENCE & THERAPEUTICS, 2024, 30 (06)
  • [33] Hyperplastic changes within the leptomeninges of the rat and monkey in response to chronic intracerebroventricular infusion of nerve growth factor
    DayLollini, PA
    Stewart, GR
    Taylor, MJ
    Johnson, RM
    Chellman, GJ
    [J]. EXPERIMENTAL NEUROLOGY, 1997, 145 (01) : 24 - 37
  • [34] Genetic polymorphisms of nerve growth factor receptor (NGFR) and the risk of Alzheimer ' s disease
    Cheng, Hui-Chi
    Sun, Yu
    Lai, Liang-Chuan
    Chen, Shih-Yuan
    Lee, Wen-Chung
    Chen, Jen-Hau
    Chen, Ta-Fu
    Chen, Hua-Hsiang
    Wen, Li-Li
    Yip, Ping-Keung
    Chu, Yi-Min
    Chen, Wei J.
    Chen, Yen-Ching
    [J]. JOURNAL OF NEGATIVE RESULTS IN BIOMEDICINE, 2012, 11
  • [35] Nanotechnological strategies for nerve growth factor delivery: Therapeutic implications in Alzheimer's disease
    Faustino, Celia
    Rijo, Patricia
    Reis, Catarina Pinto
    [J]. PHARMACOLOGICAL RESEARCH, 2017, 120 : 68 - 87
  • [36] Nerve growth factor in metabolic complications and Alzheimer's disease: Physiology and therapeutic potential
    Ding, Xiao-Wen
    Li, Rongzi
    Geetha, Thangiah
    Tao, Ya-Xiong
    Babu, Jeganathan Ramesh
    [J]. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE, 2020, 1866 (10):
  • [37] Brain and Serum Levels of Nerve Growth Factor in a Rat Model of Alzheimer's Disease
    Gelfo, Francesca
    Tirassa, Paola
    De Bartolo, Paola
    Caltagirone, Carlo
    Petrosini, Laura
    Angelucci, Francesco
    [J]. JOURNAL OF ALZHEIMERS DISEASE, 2011, 25 (02) : 213 - 217
  • [38] Is there nicotinic modulation of nerve growth factor? Implications for cholinergic therapies in Alzheimer's disease
    Rattray, M
    [J]. BIOLOGICAL PSYCHIATRY, 2001, 49 (03) : 185 - 193
  • [39] Amyloid β-Induced Nerve Growth Factor Dysmetabolism in Alzheimer Disease
    Bruno, Martin A.
    Leon, Wanda C.
    Fragoso, Gabriela
    Mushynski, Walter E.
    Almazan, Guillermina
    Cuello, A. Claudio
    [J]. JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 2009, 68 (08): : 857 - 869
  • [40] SHOULD INTRACEREBROVENTRICULAR NERVE GROWTH-FACTOR BE USED TO TREAT ALZHEIMERS-DISEASE
    SAFFRAN, BN
    [J]. PERSPECTIVES IN BIOLOGY AND MEDICINE, 1992, 35 (04) : 471 - 486